Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthomet

This article was originally published in The Gray Sheet

Executive Summary

Reinstates offer to merge with Kirschner, changing the amended proposal it withdrew July 1 to a definitive offer. The basic terms remain the same: each share of Kirschner common stock would be exchanged for 1.3 shares of Orthomet common stock and a seven-year warrant to buy an additional 1.3 shares of Orthomet common at an exercise price of $10 per share ("The Gray Sheet" July 4, p. 7). The offer expires at 5:00 p.m. Eastern Daylight Time on July 11. Kirschner must decide between the Orthomet deal and an offer from Biomet. Under the Biomet proposal, Kirschner shareholders could choose to receive either one Biomet common share (which has been trading for around $10), or $10 in cash, for each of their Kirschner common shares. Kirschner currently has 3,607,740 shares outstanding

You may also be interested in...



Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

UsernamePublicRestriction

Register

MT002558

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel